CANCELLED Due to possible updates by NIH – will be presented at a later date.
ORA Noon Conference offered via Zoom
SAVE THE DATE! April 21, 2021 at 1:00 pm
Topic: Writing NIH Other Support Pages
Required Changes as of May 25, 2021
Please register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.
OUHSC GeroScience T32 is looking for Post-Doctoral Fellows & Graduate Students
For additional information refer to the attached document.
Office of Technology Commercialization Event: Copyright, Trademark and Open Source
Wednesday, April 28, 2021 and 12 p.m. (CDT)
See attached document for additional information.
Pew-Stewart Scholar Program for Cancer Research
The Pew-Stewart Scholars Program for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The program is in line with the Stewart Trust's mission to invest in innovative, cutting-edge, basic cancer research that may accelerate and advance progress toward a cure for cancer; one application can be submitted from the Stephenson Cancer Center. Pre-proposals are being requested from interested early-stage faculty performing cancer research.
Award Amount: $300,000 in flexible support—$75,000 per year
Award Period: Four-years
Pre-Proposal Deadline: May 3, 2021
Please see attachment for information on Eligibility and Pre-Proposal Application Details.
Should you have any questions, please contact CancerResearch@ouhsc.edu.
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email email@example.com or firstname.lastname@example.org).
- Company (requested anonymity) is seeking to engage with academic partners to develop lymphatic-based disease solutions – focusing on minimally invasive treatments. Submission entails a 1-pg non-confidential summary of technology (deadline 5/7/2021).
- Reckitt is seeking to engage with academic partners to 1) develop approaches to enhance oral drug delivery into the pharyngeal, esophageal, or colon; 2) enhance the safety of OTC medications, or 3) develop natural/non-medicated solutions for upper and lower GI conditions, sore throat, cough, cold, flu, and pain. Submission entails a 1-pg non-confidential summary of technology (deadline 5/27/2021)
- Pfizer’s Centers for Therapeutic Innovation (https://www.pfizercti.com) is seeking collaborative proposals for developing novel therapeutic targets with application in 1) oncology: tumor targeted, immuno-oncology, cancer vaccines; 2) internal medicine: obesity/cachexia, heart failure, diabetic/CKD, NASH/T2D; 3) inflammation and immunology: rheumatology, gastroenterology, medical derm; or 4) rare disease: cardiology, neuro-musc., metabolic, hematology. Preference is for novel biological targets supported by in vivo and in vitro models, enabling genetics and mechanistic insights, translational biochemical or cellular assay and biomarkers. Out of scope: drug repurposing, standalone biomarker assays/platforms, medical devices, cell-based therapies.
Proposal template available upon request (submission deadline 6/18/21).
UPDATE: HSC COVID-19 Response Plan - effective April 13, 2021
This revised Plan (https://www.ouhsc.edu/coronavirus) includes some minor clarifications to current HSC COVID-19 protocols, as well as some more substantive revisions, including:
Section I Telecommuting – Telecommuting in response to COVID-19 is being phased out.
- By June 2, 2021, at least 50% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By July 1, 2021, at least 75% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus.
- By August 1, 2021, 100% of the program’s/area’s workforce will have resumed their regular (pre-COVID) schedule on campus
Section III Social Distancing and Gatherings – Effective June 1, social distance measurement will be 3 feet, except in patient care and eating areas which remain at 6 feet.
-This information is included in the Response Plan now for planning purposes. Our medical and public health experts are hopeful that more students and employees will be able to complete their vaccine series in the next few weeks.
-The 6-foot requirement remains in effect until June 1. Operations will replace signs at that time.
Section V Cleaning Facilities and Equipment – Updated to reflect changes to cleaning protocols in response to recent CDC guidance on cleaning as well as to scientific data regarding COVID-19 surface transmissions. There are also changes to reflect current clinic screening processes (Section VIII) and international travel (Sections VII and IX), as well as a number of non-substantive changes made for clarification.
Please ensure your area’s Return to Service Plans are updated to reflect these changes.
PRESBYTERIAN HEALTH FOUNDATION GRANTS – REQUEST FOR APPLICATIONS
The Presbyterian Health Foundation (PHF) will fund $4.15M in grants for 2021. Information on the PHF Grant Programs for Spring 2021 and Guidelines and Application for each of the grant programs listed below may be found at https://research.ouhsc.edu/Resources/PHF-Funding-2021. All guidelines have been recently updated to reflect that funds may not be requested for student tuition and fees. If you have any questions, please email ORA4PHF@ouhsc.edu.
April 30, 2021
REMINDER ON COVID-19 MITIGATION STRATEGIES IN THE RESEARCH ENVIRONMENT
With the current increase in COVID-19 cases across Oklahoma, this is a good time to do the following:
- Encourage everyone on your team to telecommute as much as possible; reducing the number of individuals in buildings and the research environment will help in reducing potential transmission of the virus.
- Follow your approved COVID-19 Standard Operating Procedures for your laboratory; be certain these are current and are posted on the lab door and inside the laboratory.
- Familiarize yourself with OU Health Sciences Center COVID-19 Resources https://www.ouhsc.edu/coronavirus).
- Follow all masking and social distancing guidelines as described in the OUHSC COVID-19 Return Plan (https://www.ouhsc.edu/coronavirus); wash your hands often.
- It’s a good practice to follow the HSC’s COVID-19 protocols even when you are home or in the community – masking, social distancing, and good hand hygiene help protect you, your colleagues, and your loved ones.
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website (http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor, Department of Microbiology and Immunology, OUHSC ( email@example.com ).
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at: https://research.ouhsc.edu/Resources/COVID-Research-Updates
Reminder: Required use of FORMS-F Application Forms for Application Submission (NOT-OD-21-104)
Update on Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research (NOT-OD-21-111)
Notice of Pre-Application Webinar for Companion Announcements PAR-21-207 and RFA-AG-22-016 Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer’s Disease and Related Dementias (AD/ADRD) (NOT-AG-21-023)
Updated Guidance Regarding Administration of the NCI Outstanding Investigator Award (R35) Program
Updated NCI Guidance Concerning the Mentored Clinical Scientist Research Career Development Award: Percent Effort of Surgeon-Scientists for K08 awards from NCI (NOT-CA-21-054)
Continuation of Temporary Extension of Eligibility for the NIH K99/R00 Pathway to Independence Award During the COVID-19 Pandemic (NOT-OD-21-106)
Notice of Pre-Application Webinar for Funding Opportunities on Transformative Research to Address Health Disparities and Advance Health Equity (NOT-RM-21-025)
Notice of Pre-Application Webinar for Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth), RFA-TW-21-001 (U01 Clinical Trial Optional) and RFA-TW-21-002 (U2R Clinical Trial Optional) (NOT-TW-21-006)
Request for Information (RFI): Research Challenges and Needs in Developing Chronomedicine for Health and Diseases (NOT-CA-21-042)
Notice of NIAAA Participation in NOT-OD-21-087 "Notice of Special Interest (NOSI): Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being" (NOT-AA-21-013)
Notice of NIAAA Participation in NOT-OD-21-085 "Notice of Intent to Reissue PAR-18-307 " Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)" as a Notice of Special Interest (NOSI)" (NOT-AA-21-014)
Notice of NIAAA Participation in NOT-OD-21-086 "Notice of Intent to Reissue PAR-18-324 "Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)" as a Notice of Special Interest (NOSI)" (NOT-AA-21-015)
Notice of Change: Extension and Additional Key Dates for NIAAA RFA-AA-21-002 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)" (NOT-AA-21-025)
Notice of Change: Extension and Additional Key Dates for NIAAA RFA-AA-21-003 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)" (NOT-AA-21-026)
Notice of Change: Extension and Additional Key Dates for NIAAA RFA-AA-21-004 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)" (NOT-AA-21-027)
Notice of NCI's Participation in PAR-21-169, "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)" (NOT-CA-21-056)
Notice of Change: Receipt date added for RFA-EB-20-002, "BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) (NOT-EB-21-006)
Notice of Correction for RFA-LM-21-001, "NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science (T15 Clinical Trial Not Allowed)" (NOT-LM-21-007)
Notice of Clarification of Resubmission Due dates for RFA-RM-21-012, Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) (NOT-RM-21-024)
Notice of Addition of Requested Institutional Information for RFA-RM-21-022 - Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (NOT-RM-21-026)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional) (NOT-AA-21-020)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Core (U24) (Clinical Trial Not Allowed) (NOT-AA-21-021)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Core (U24 Clinical Trial Not Allowed) (NOT-AA-21-022)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Core (U24 Clinical Trial Not Allowed) (NOT-AA-21-023)
Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional) (NOT-AA-21-024)
Notice of Intent to Publish a Funding Opportunity Announcement for Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (U24 Clinical Trials Not Allowed) (NOT-HG-21-027)
Notice of Special Interest (NOSI): Telehealth in Cancer Care (NOT-CA-21-043)
Notice of Special Interest (NOSI): Administrative Supplement for Modifiable Factors Potentially affecting the Cost of Cancer Treatment (NOT-CA-21-055)
Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-21-041)
Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings (NOT-MH-21-230)
Notice of Special Interest (NOSI): Administrative Supplements for Workforce Development at the Interface of Information Sciences, Artificial Intelligence and Machine Learning (AI/ML), and Biomedical Sciences (NOT-OD-21-079)
Notice of Special Interest (NOSI): Research Supplements to Promote Diversity in Environmental influences on Child Health Outcomes (ECHO) Program Research (Admin Supp - Clinical Trial Not Allowed) (NOT-OD-21-093)
Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data (NOT-OD-21-094)
Notice of Special Interest (NOSI): Administrative Supplements for Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) Phase I Projects to Address Vaccine Hesitancy and Uptake (NOT-OD-21-101)
Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (Emergency Supplement - Clinical Trial Optional) (NOT-OD-21-103)
Notice of Special Interest (NOSI): Topic Areas for PAR-21-203, Limited Competition: Clinical and Translational Science Award (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed) (NOT-TR-21-025)
Please Note: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-Eligible States (C06 Clinical Trial Not Allowed) (PAR-21-159) - Deadline January 6, 2022
Enhancing NIDCD's Extramural Workforce Diversity through Research Experiences (R25 Clinical Trial Not Allowed) (PAR-21-186) – Deadline May 28, 2021 and September 24, 2021
Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R21 Clinical Trial Optional) (PAS-21-215) – Deadline October 16, 2021
Identification of Positive Valence System Related Targets for Novel Suicide Prevention Approaches (R01 - Clinical Trial Optional) (PAS-21-216) – Deadline October 05, 2021
3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) (RFA-CA-21-037) Deadline June 30, 2021 and November 22, 2021
Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)
(RFA-HD-22-013) - Deadline July 29, 2021
Coordinating Center for the NICHD Population Dynamics Centers Research Infrastructure Program FY 2022 (R24 Clinical Trial Not Allowed) (RFA-HD-22-014) – Deadline July 29, 2021
Biomarker Research to Support Fertility Regulation Development by Small Business (R43 Clinical Trial Optional) (RFA-HD-22-018) - Deadline July 29, 2021
Centers for Multiple Chronic Diseases Associated with Health Disparities: Prevention, Treatment, and Management (P50 Clinical Trial Required) (RFA-MD-21-007) – Deadline June 10, 2021
NIMHD Multiple Chronic Disease Disparities Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed) (RFA-MD-21-008) - Deadline June 11, 2021
Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Black Children and Adolescents (R01 Clinical Trial Optional) (RFA-MH-21-185) – Deadline June 29, 2021
Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Black Children and Adolescents (R34 Clinical Trial Optional) (RFA-MH-21-186) - Deadline June 29, 2021
Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R01 Clinical Trial Optional) (RFA-MH-21-187) - Deadline June 29, 2021
Systems-Level Risk Detection and Interventions to Reduce Suicide, Ideation, and Behaviors in Youth from Underserved Populations (R34 Clinical Trial Optional) (RFA-MH-21-188) - Deadline June 29, 2021
Building Interdisciplinary Research Careers in Women's Health Program (BIRCWH) (K12 Clinical Trial Optional) (RFA-OD-21-006) - Deadline June 11, 2021
Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional) (RFA-OD-21-008) - Deadline July 07, 2021
Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional) (RFA-OD-21-009) – Deadline July 07, 2021
OTHER FEDERAL DEADLINES
Department of Defense (DOD) – Epilepsy Research Program (ERP) – Idea Development Award –
Required Preapplication due June 14, 2021
DOD – ERP – Quality of Life Award – Required Preapplication due June 14, 2021
DOD – ERP – Research Partnership Award – Required Preapplication due June 14, 2021
DOD – Tuberous Sclerosis Complex Research Program (TSCRP) – Exploration Hypothesis Development Award
Required Preapplication due June 17, 2021
DOD – TSCRP – Idea Development Award – Required Preapplication due June 17, 2021
DOD – TSCRP – Clinical Translational Research Award – Required Preapplication due June 17, 2021